JP2017209427A - Percutaneous administration device and medicament administration instrument - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a percutaneous administration device and medicament administration instrument capable of smoothly administering a medicament.SOLUTION: A percutaneous administration device 10 includes: a cylindrical base body 21 for passing a medicament, the base body 21 having a support surface 21S at one of two cylindrical ends of the base body 21; a projection part 22 projecting from the support face 21S, the projection part 22 formed with a through-hole 23 which penetrates through the projection part 22 in an extension direction of the projection part 22 and is communicated with an internal space of the base body 21; and an elastic member 30 located on the support face 21S, the elastic body having tackiness.SELECTED DRAWING: Figure 2

Description

  The present invention relates to a transdermal administration device used for administration of a drug and a drug administration device including the transdermal administration device.

  The transdermal administration device includes an administration unit for administering a drug from the skin to the administration target. A microneedle, which is an example of an administration unit, has a protrusion having a needle shape on the surface of a base body (see, for example, Patent Document 1). In the administration method using microneedles, a hole is formed in the skin by piercing the skin with a protrusion, and the drug is administered by feeding the drug into the skin through this hole. If the administration method using microneedles, the length of the protrusion is very small, so that pain when pores are formed in the skin can be suppressed compared to the method of administering the drug subcutaneously using an injection needle. .

  In one administration method using a microneedle, a microneedle having a through-hole penetrating the base portion and the protrusion in the extending direction of the protrusion is used, and a liquid drug is administered into the skin through the through-hole. (For example, see Patent Document 2). Such a microneedle is used by being attached to a syringe like an injection needle, for example.

Japanese Patent No. 4276691 Japanese Patent Laid-Open No. 2005-21677

By the way, there is a stratum corneum having a barrier function, which is a function of protecting the body from external stimuli and harmful substances from the outside, on the surface of the skin of a drug administration target. In order to accurately deliver the drug into the body of the administration subject, the user of the transdermal administration device must place the microneedle in the skin with a force that allows the protrusion to penetrate the stratum corneum, which is harder than the tissue inside the skin. It is necessary to press. However, when the microneedle is pressed against the skin by such a pressing force, the tissue in the skin is pressed and becomes clogged, so that the drug that has come out of the through hole of the protruding portion does not easily penetrate into the tissue.
An object of the present invention is to provide a transdermal administration device and a drug administration device capable of smoothly administering a drug.

  A transdermal administration device that solves the above-described problem is a cylindrical base portion through which a drug passes, the base portion having a support surface at one of two cylindrical ends of the base portion, and a protrusion protruding from the support surface A protrusion formed in a through hole that extends through the protrusion in the extending direction of the protrusion and communicates with the internal space of the base portion; And an elastic member that is an elastic body.

  According to the above configuration, the elastic member is compressed between the support surface and the surface of the skin when the transdermal administration device is pressed against the skin to such an extent that the protrusion is stuck in the skin to be administered. Sticks to the surface of the skin. When the pressing force applied to the transdermal administration device is weakened, the shape of the elastic member is restored, so that the base portion and the protrusion move away from the surface of the skin, and the transdermal administration device The pressure on the skin due to is reduced. At this time, since the elastic member is adhered to the surface of the skin, it is possible to prevent the support surface from being excessively separated from the surface of the skin and, in turn, the protruding portion from slipping out of the skin. Therefore, while applying a force to penetrate the stratum corneum and piercing the skin into the skin, weakening the pressure on the skin while preventing the pierced protrusion from coming out of the skin, it is easy for the drug to penetrate into the skin By administering the drug through the through-hole in this state, it is possible to smoothly administer the drug.

The said structure WHEREIN: The said elastic member may surround the circumference | surroundings of the said projection part seeing from the direction facing the said support surface.
According to the above configuration, since the transdermal administration device sticks to the skin at a position surrounding the protrusion, the stability of the position of the protrusion with respect to the skin is enhanced.
In the above configuration, the transdermal administration device may include a plurality of protrusions, and the elastic member may surround a set of the plurality of protrusions when viewed from a direction facing the support surface.

According to the above configuration, the elastic member can suppress the complexity of the shape of the elastic member and the difficulty in obtaining the accuracy of the shape of the elastic member as compared to the configuration in which the elastic member surrounds the protrusions one by one. The elastic member can be easily formed.
In the above configuration, the transdermal administration device may include a plurality of the protrusions, and the elastic member may surround the protrusions one by one when viewed from a direction facing the support surface.

  According to the above configuration, it is easy to ensure a large area occupied by the elastic member on the support surface, as compared with a form in which one elastic member surrounds a set of a plurality of protrusions. Therefore, since the area of the elastic member attached to the surface of the skin can be easily secured, the stability of the position of the protrusion with respect to the skin is enhanced.

In the above configuration, the transdermal administration device may include a plurality of the elastic members.
According to the said structure, the freedom degree of adjustment about the arrangement | positioning of an elastic member and the function which an elastic member exhibits is raised.
In the above configuration, the plurality of elastic members include a plurality of elastic members having different characteristics, and the characteristics include an elastic modulus of the elastic member, an adhesive property of the elastic member, and an extension of the protrusion. It may be at least one of the maximum lengths of the elastic member in the direction.

According to the above configuration, the length of the protrusion in the skin can be adjusted according to the variation in the pressing force depending on the position in the support surface, the variation in the easiness of the skin in the administration site of the drug, etc. The strength with which the transdermal administration device sticks to the skin can be adjusted according to the position within the support surface.
The said structure WHEREIN: The said elastic member may have several site | parts from which the length of the said elastic member differs in the direction where the said protrusion part extends, respectively.

  According to the above configuration, since the length of the elastic member is different at each part of the elastic member, the length of the protruding portion that pierces the skin and the elongation of the skin can be adjusted according to the position in the support surface, or the transdermal administration device It is possible to adjust how the skin sticks to the skin.

  A drug administration device that solves the above-described problem is a drug administration device that includes the transdermal administration device and an administration aid wrapped around an administration target of the drug, the administration aid having a band portion that extends in a band shape. An opening formed in the band portion, the opening having a size that allows the support surface of the transdermal administration device to be inserted, and a lid that can be opened and closed so as to close the opening. And a fixing portion configured such that both ends of the band portion in the extending direction of the band portion can be fixed to each other.

  According to the above configuration, after the administration aid is wrapped around the administration target of the drug, the transdermal administration device is inserted into the opening, the protrusion is pierced into the skin in the opening, and the drug is administered, whereby It is possible to easily position the skin administration device, that is, the position to administer the drug. In addition, the stability of the position of the transdermal administration device with respect to the skin during the administration of the drug is enhanced. Furthermore, the penetration of the administered drug into the body is assisted by closing the opening with the lid after the administration of the drug. Therefore, smooth drug administration using the transdermal administration device can be facilitated.

  ADVANTAGE OF THE INVENTION According to this invention, a chemical | medical agent can be smoothly administered with a transdermal administration device.

The exploded perspective view which shows the whole structure of a transdermal administration device about one Embodiment of a transdermal administration device. Sectional drawing which shows the cross-section in the transdermal administration device of one Embodiment. The top view which shows the planar structure in the transdermal administration device of one Embodiment. The figure which shows typically the state by which the transdermal administration device of one Embodiment was pressed on skin. The figure which shows typically the state by which the pressing force was weakened after the transdermal administration device of one Embodiment was pressed on skin. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. The top view which shows the other example of the planar structure in the transdermal administration device of one Embodiment. Sectional drawing which shows the other example of the cross-section in the transdermal administration device of one Embodiment. Sectional drawing which shows the other example of the cross-section in the transdermal administration device of one Embodiment. Sectional drawing which shows the other example of the cross-section in the transdermal administration device of one Embodiment. Sectional drawing which shows the other example of the cross-section in the transdermal administration device of one Embodiment. Sectional drawing which shows the other example of the cross-section in the transdermal administration device of one Embodiment. Sectional drawing which shows the other example of the cross-section in the transdermal administration device of one Embodiment. Sectional drawing which shows the other example of the cross-section in the transdermal administration device of one Embodiment. The top view which shows the planar structure of the administration assistance tool of one Embodiment. The figure which shows typically the state with which the administration assistance tool of one Embodiment was mounted | worn with the limbs of the administration object of a chemical | medical agent. The figure which shows typically the state with which the administration assistance tool of one Embodiment was mounted | worn with the limbs of the administration object of a chemical | medical agent. The figure which shows the structure of the chemical | medical agent administration instrument of one Embodiment with a syringe. The perspective view which shows the transdermal administration device of one Embodiment in the state by which the cover member was affixed. The figure which shows the procedure in which a chemical | medical agent is administered using the chemical | medical agent administration apparatus of one Embodiment, Comprising: The figure which shows the state by which the administration assistance tool was wound around the administration subject of a chemical | medical agent. The figure which shows the procedure in which a chemical | medical agent is administered using the chemical | medical agent administration instrument of one Embodiment, Comprising: The figure which shows the state by which the transdermal administration device was pressed on skin. The figure which shows the procedure in which a chemical | medical agent is administered using the chemical | medical agent administration instrument of one Embodiment, Comprising: The figure which shows the state by which the pressing force was weakened after the transdermal administration device was pressed on skin. The figure which shows the procedure in which a chemical | medical agent is administered using the chemical | medical agent administration apparatus of one Embodiment, Comprising: The figure which shows typically the state by which the administration site | part of the chemical | medical agent was protected after administration of a chemical | medical agent.

1 to 52, an embodiment of a transdermal administration device and a drug administration device will be described.
[Configuration of transdermal administration device]
The configuration of the transdermal administration device will be described with reference to FIGS.
As shown in FIG. 1, the transdermal administration device 10 includes a microneedle 20 that is an example of an administration unit, and an elastic member 30.

  The microneedle 20 includes a cylindrical base portion 21 and a protruding portion 22 protruding from the base portion 21. The elastic member 30 has an annular shape and is disposed at a position surrounding the protrusion 22.

  As shown in FIG. 2, the base portion 21 has a support surface 21 </ b> S as an end surface at one of the two cylindrical ends of the base portion 21. Of the two cylinder ends of the base portion 21, the cylinder end opposite to the support surface 21S is opened.

  The outer shape of the base portion 21 is not particularly limited, and the base portion 21 may have a cylindrical shape or a rectangular tube shape. And the support surface 21S should just have the shape according to the shape of the base | substrate part 21. FIG. Moreover, the base | substrate part 21 may have a part from which an outer diameter changes gradually between two cylinder ends, and a part from which an outer diameter changes in steps. In the example shown in FIGS. 1 to 3, the base portion 21 has a cylindrical shape, and the support surface 21 </ b> S has a circular shape.

  The protrusion 22 protrudes from the support surface 21 </ b> S, and the support surface 21 </ b> S supports the base end of the protrusion 22. The protrusion 22 extends in a direction opposite to the direction in which the base portion 21 extends in a cylindrical shape with respect to the support surface 21S. The shape of the protrusion 22 is not particularly limited as long as it can pierce the skin. The protrusion 22 may have a conical shape or a pyramid shape, or may have a cylindrical shape or a polygonal prism shape. You may do it. In the example shown in FIGS. 1 to 3, the protrusion 22 has a substantially conical shape. Further, the number of the protrusions 22 included in the microneedle 20 may be one or plural. In the example shown in FIGS. 1 to 3, the microneedle 20 includes a plurality of protrusions 22.

A through hole 23 is formed in the protrusion 22 so as to penetrate the protrusion 22 in the direction in which the protrusion 22 extends. When viewed from the direction facing the support surface 21S, the through hole 23 may be located at the center of the protrusion 22 or may be disposed at a position different from the center. The through hole 23 penetrates the side wall having the support surface 21 </ b> S in the base portion 21 and reaches the inside of the base portion 21. That is, the through hole 23 communicates with the internal space of the base portion 21, and the inner surface of the base portion 21 and the surface that defines the through hole 23 form a drug flow path. During the administration of the drug, the drug supplied to the internal space of the base portion 21 passes through the through hole 23 and exits from the opening at the tip portion of the protrusion 22 to the outside of the transdermal administration device 10.
The elastic member 30 is an elastic body having adhesiveness, and is disposed at a position surrounding the periphery of the protruding portion 22 by the support surface 21S.

  The maximum length H of the protrusion 22 is the maximum length of the protrusion 22 in the direction in which the protrusion 22 extends, that is, the direction orthogonal to the support surface 21S, that is, from the support surface 21S to the tip of the protrusion 22. Is the length of The maximum length T of the elastic member 30 is the maximum length of the elastic member 30 in the extending direction of the protrusion 22, that is, the length from the support surface 21 </ b> S to the tip of the elastic member 30. In the example shown in FIGS. 1 to 3, the length of the elastic member 30 in the extending direction of the protrusion 22 is constant in the elastic member 30. The maximum length H of the protrusion 22 is, for example, a length in the range of 100 μm or more and 3000 μm or less, and the maximum length T of the elastic member 30 is, for example, a length in the range of 50 μm or more and 2500 μm or less.

  The maximum length H of the protrusion 22 is preferably larger than the maximum length T of the elastic member 30. That is, it is preferable that the tip of the protrusion 22 protrudes from the elastic member 30 when viewed from the direction along the support surface 21 </ b> S. With such a configuration, when the drug is administered, since the tip of the protrusion 22 comes into contact with the skin to be administered before the elastic member 30, the protrusion 22 is likely to be stuck into the skin.

  The maximum length H of the protrusion 22 is the drug administration position in the cross-sectional direction of the skin, that is, the depth at which the tip of the protrusion 22 should be positioned when the drug is being administered to the skin, or the maximum length T of the elastic member 30. And is set according to the elastic modulus. The maximum length T of the elastic member 30 is set according to the elastic modulus of the elastic member 30, the maximum length H of the protrusion 22, and the administration position of the drug in the skin cross-sectional direction.

  The maximum width D of the protrusion 22 is the maximum value of the length of the protrusion 22 in the direction along the support surface 21 </ b> S of the base body 21. For example, when the protrusion 22 has a conical shape, the diameter of a circle defined by the bottom of the protrusion 22 is the maximum width D of the protrusion 22. The maximum width D of the protrusion 22 is, for example, a length in the range of 100 μm or more and 1000 μm or less, and the aspect ratio A (A = H / D) that is the ratio of the maximum length H to the maximum width D of the protrusion 22 is 1 or more and 10 or less are preferable.

  FIG. 3 is a view of the transdermal administration device 10 viewed from the direction facing the support surface 21S, and shows the elastic member 30 with dots. As shown in FIG. 3, the elastic member 30 is disposed along the outer edge of the support surface 21 </ b> S and surrounds a set of the plurality of protrusions 22.

[Drug administration using transdermal device]
With reference to FIG. 4 and FIG. 5, the procedure of the administration of the medicine using the transdermal administration device 10 will be described.
As shown in FIG. 4, the tip of the protrusion 22 is directed to the surface of the skin Sk, and the transdermal administration device 10 is pressed against the skin Sk. At this time, the transdermal administration device 10 is applied with such a force that the protrusion 22 penetrates the stratum corneum of the skin. As a result, the protrusion 22 penetrates the stratum corneum and pierces the skin Sk, and the elastic member 30 receives a pressing force and is compressed in the extending direction of the protrusion 22. At this time, the elastic member 30 is sandwiched between the support surface 21S and the surface of the skin Sk, and the elastic member 30 is in contact with the surface of the skin Sk.

  As shown in FIG. 5, when the protrusion 22 is pierced into the skin Sk, the pressure applied to the transdermal administration device 10 is released. Thereby, the elastic member 30 is restored, and the size of the elastic member 30 returns to the normal state before receiving the pressure, and the base portion 21 moves away from the surface of the skin Sk as the thickness of the elastic member 30 increases. It moves to. At the same time, the position of the protruding portion 22 also returns toward the surface of the skin Sk, and the length of the portion of the protruding portion 22 that is stuck in the skin Sk is shortened. At this time, since the elastic member 30 is adhered to the surface of the skin Sk by the adhesive force, the protrusion 22 is prevented from slipping out of the skin Sk or the protrusion 22 being inclined in the skin Sk.

  Thereby, since the press with respect to skin Sk is cancelled | released, crushing of skin Sk is eliminated, As a result, it becomes easy to osmose | permeate a chemical | medical agent in skin. Thus, the medicine is administered in a state where the pressure is released. The medicine is supplied from the outside to the internal space of the base portion 21, passes through the base portion 21 and the through hole 23, exits from the tip of the protruding portion 22, and is diffused into the skin.

  In such a configuration, the maximum length H of the protrusion 22 is the difference between the maximum length H of the protrusion 22 and the maximum length T of the elastic member 30, in other words, the elastic member 30 in the normal state in the protrusion 22. The length of the protruding portion is set so as to be the length from the surface of the skin to be administered to the portion where the tip of the protrusion 22 should be positioned when the drug is administered.

  The administration of the drug does not have to be performed in a state where the elastic member 30 is completely restored and its size returns to the normal state. That is, the state in which the elastic member 30 is most compressed in the extending direction of the protrusion 22 by the pressing force for inserting the protrusion 22 into the skin Sk, in other words, the state in which the protrusion 22 is deeply inserted into the skin Sk. The elastic member 30 may be administered in a state where the elastic member 30 is compressed as compared with the normal state as long as the elastic member 30 is restored as the pressing force is weakened. . Even in such a state, since the pressing force applied to the skin Sk is weaker than the state where the protrusion 22 is deeply pierced into the skin Sk, the drug is likely to penetrate into the skin.

  In this case, the maximum length H of the protrusion 22 is determined by taking into consideration the maximum length T and elastic modulus of the elastic member 30, the hardness and elastic modulus of the skin at the drug administration site, the applied pressing force, and the like. In the state where the tip of the protrusion 22 is located at the site where the medicine is to be administered, that is, the length of the part of the protrusion 22 that protrudes from the elastic member 30 and pierces the skin is What is necessary is just to set so that it may become the depth which should be administered.

[Transdermal Device Material and Manufacturing Method]
The material and manufacturing method of each part which comprises the above-mentioned transdermal administration device 10 are demonstrated.
The material constituting the microneedle 20 is not particularly limited. Examples of the material include polylactic acid, polyvinyl chloride, polyethylene, polypropylene, cyclic polyolefin, polystyrene, poly- (4-methylpentene-1), polycarbonate, and acrylic resin. Polyesters such as acrylonitrile-butadiene-styrene copolymer, polyethylene terephthalate and polyethylene naphthalate, for example, polyamides such as nylon 6, nylon 6,6, nylon 310, nylon 12, and resins such as butadiene-styrene copolymer are used. . The material constituting the microneedle 20 is preferably biocompatible. The microneedle 20 is preferably transparent or translucent in order to ensure internal visibility.

  The microneedle 20 may be formed integrally as a whole, or may be formed by assembling a plurality of members. In order to integrally form the microneedle 20 using the above-described material, for example, a known melt molding processing technique such as injection molding, extrusion molding, imprinting, hot embossing, or casting may be used. The through hole 23 can be formed by a known fine processing technique such as micro drilling or laser processing.

  Further, as a method for forming the microneedles 20 other than melt molding, a method of forming the outer shape of the protrusion 22 by etching after forming holes in the substrate may be used. Various known techniques such as wet etching, dry etching, laser processing, and machining can be used for forming the holes in the substrate. Then, a needle-like structure is formed on the substrate by performing etching using an etching mask whose thickness continuously changes from the central portion toward the periphery in the region where the protrusion 22 is to be formed.

  In this case, the material constituting the microneedle 20 may be any material that can be processed by etching such as wet etching or dry etching. Examples of such a material include metals such as titanium, aluminum, and stainless steel, polycarbonate, polystyrene, and the like. , Synthetic resins such as acrylic resin and fluororesin, and silicon.

Although the material which comprises the elastic member 30 will not be specifically limited if it is a material which can implement | achieve desired elasticity and adhesiveness, For example, it is preferable that a urethane gel is used. The elastic member 30 has, for example, a hardness (Shore A) of 1 or more and 5 or less, a 30% compressive strength (N / mm ² ) of 10 or more and 100 or less, and a compression elastic modulus (N / mm ² ) of 100 or more and 500 or less, 180 ° Peel test adhesiveness (N / 25 mm) is preferably 2 or more and 10 or less, and if urethane gel is used as a constituent material of the elastic member 30, such characteristics can be suitably realized. As such a urethane gel, for example, a gel tack sheet manufactured by Exceal is used, and the elastic member 30 is formed by punching the sheet into an annular shape.

[Modification of shape and arrangement of elastic member]
A modification of the shape and arrangement of the elastic member 30 will be described with reference to FIGS. 6 to 36, the elastic member 30 is shown with dots.
The elastic member 30 having the above-described configuration has an annular shape with a constant radial width, but the elastic member 30 only needs to surround a set of the plurality of protrusions 22 and is opposed to the support surface 21S. The region surrounded by the elastic member 30 as viewed from the direction to be not necessarily circular.

  For example, the region surrounded by the elastic member 30 may have a substantially rectangular shape as shown in FIG. 6, or a shape having an edge that curves according to the arrangement of the protrusions 22 as shown in FIG. 7. There may be. In short, as viewed from the direction facing the support surface 21S, the elastic member 30 only needs to define an area larger than the area where the plurality of protrusions 22 are arranged at the center. In other words, the elastic member 30 should just have an opening larger than the area | region where the some projection part 22 is arrange | positioned.

  In each of the above embodiments, the elastic member 30 surrounds a set of the plurality of protrusions 22, but as shown in FIGS. 8 and 9, the elastic member 30 individually includes the plurality of protrusions 22 one by one. It may be surrounded by That is, the elastic member 30 may have an opening larger than the area where each protrusion 22 is arranged at each arrangement position of the plurality of protrusions 22.

  In the configuration in which the elastic member 30 surrounds the plurality of protrusions 22 one by one, the elastic member 30 occupies the support surface 21 </ b> S compared to the configuration in which the elastic member 30 surrounds the set of the plurality of protrusions 22. It is easy to secure a large area. Therefore, since the area of the elastic member 30 that adheres to the skin can be easily secured during the administration of the drug, the stability of the position of the protrusion 22 relative to the skin during the administration of the drug is improved.

  In addition, when a drug is administered using the transdermal administration device 10 according to the present embodiment, the skin is lightly pressed by the elastic member 30 because the elastic member 30 is attached to the skin. The loosening is suppressed, and the protrusion 22 is easily stuck to a desired depth. In the configuration in which the elastic member 30 surrounds the plurality of protrusions 22 one by one, the effect of suppressing such skin sag can be obtained. The degree of skin sag varies depending on the administration site of the drug in the limbs, the age of the administration target, and the like. Therefore, the elastic member 30 surrounds the plurality of protrusions 22 one by one according to the administration site of the administration target. It is preferable that the configuration or the configuration surrounding the set of the plurality of protrusions 22 is selected and the arrangement area of the elastic member 30 on the support surface 21S is set.

  In each of the above embodiments, one protrusion 22 is located at the center of the support surface 21S, and a plurality of protrusions 22 are disposed on the ring surrounding the protrusion 22, but the support surface 21S The protrusion 22 may not be arranged at the center.

  For example, as illustrated in FIG. 10, the protrusion 22 is not disposed at the center of the support surface 21 </ b> S, and a plurality of protrusions 22 are disposed on one ring at the outer periphery surrounding the center, and the elastic member 30. May surround a set of a plurality of protrusions 22. In this case, neither the protrusion part 22 nor the elastic member 30 is arrange | positioned in the center part of 21 S of support surfaces. Further, for example, as shown in FIG. 11, the protrusion 22 is not disposed at the center portion of the support surface 21 </ b> S, the plurality of protrusions 22 are disposed on one ring at the outer peripheral portion, and the elastic member 30 includes a plurality of elastic members 30. The protrusions 22 may be surrounded one by one. In this case, the elastic member 30 is disposed at the center of the support surface 21S.

  According to such a configuration, since the protrusions 22 are disposed only on the outer peripheral portion of the support surface 21S, the pressing force applied to these portions when the protrusion 22 is punctured between the central portion and the outer peripheral portion of the support surface 21S. Even if the sizes are different or the characteristics such as the elasticity of the skin facing the support surface 21S are different, it is possible to suppress variations in the depth at which each protrusion 22 pierces the skin.

Moreover, when the projection part 22 with which the microneedle 20 is provided is one, the area | region which the elastic member 30 surrounds is an area | region of the magnitude | size which can arrange | position only one projection part 22, as FIG.12 and FIG.13 shows. Alternatively, as shown in FIG. 14, the area may be larger than a size where only one of the protrusions 22 can be arranged. When viewed from the direction facing the support surface 21S, the region surrounded by the elastic member 30 may be similar to the protrusion 22 as shown in FIG. 12, or similar as shown in FIG. 13 and FIG. The shape may be different from the shape.
In each of the above embodiments, the configuration in which the shape of the protruding portion 22 is a substantially conical shape has been illustrated, but the same elastic member 30 may be disposed even when the protruding portion 22 has another shape.

  For example, even when the protrusion 22 has a substantially quadrangular pyramid shape, the elastic member 30 may surround a set of the plurality of protrusions 22 as shown in FIG. 15 and FIG. As shown in FIG. 18, the plurality of protrusions 22 may be surrounded one by one.

Moreover, the area | region which the elastic member 30 partitions may comprise the predetermined | prescribed mark, a pattern, a character, etc.
For example, in the example shown in FIGS. 19 to 21, the support surface 21 </ b> S is provided with one protrusion 22 at the center thereof, and a plurality of protrusions 22 are formed on the ring surrounding the center protrusion 22. positioned. The region surrounded by the elastic member 30 has a star shape having the same number of protruding vertices as the number of the protruding portions 22 surrounding the central protruding portion 22.

  Further, for example, in the example shown in FIG. 22, a plurality of protrusions 22 are located on one annular ring on the outer peripheral portion of the support surface 21 </ b> S. The elastic member 30 divides a triangular area in the area where each protrusion 22 is arranged, surrounds the plurality of protrusions 22 for each protrusion 22, and as a whole by an opening or the like formed in the center thereof. Constructs a sun-inspired pattern.

  The first elastic member 31 and the second elastic member 32, which are two types of elastic members 30 having different characteristics, may be disposed on the support surface 21S. For example, the first elastic member 31 and the second elastic member 32 are different in at least one of the magnitude of elastic modulus, the strength of adhesiveness, and the maximum length T of the elastic member 30.

  As shown in FIGS. 23 and 24, for example, the first elastic member 31 is disposed along the outer edge of the support surface 21S and surrounds a set of the plurality of protrusions 22, and the second elastic member 32 is provided with the support surface 21S. It arrange | positions in the position which surrounds the projection part 22 located in the center. The shape of the region surrounded by the first elastic member 31 and the shape of the region surrounded by the second elastic member 32 are not particularly limited as in the elastic member 30 in each of the above embodiments.

  The characteristics of the first elastic member 31 and the second elastic member 32 are set according to, for example, variation due to the position of the pressing force received by the protrusion 22 or variation in the easiness of skin elongation within the drug administration site. Is done.

  For example, due to the shape of the base portion 21 and the arrangement of the protrusions 22, the protrusion 22 positioned on the outer peripheral portion receives a greater pressing force than the protrusion 22 positioned at the center of the support surface 21 </ b> S. There is. In this case, the protrusion 22 positioned on the outer peripheral portion is more likely to pierce the skin deeper than the protrusion 22 positioned in the center of the support surface 21S. Therefore, the first elastic member 31 located on the outer peripheral portion of the support surface 21S is made an elastic body having a larger elastic modulus than the second elastic member 32 located on the center portion of the support surface 21S, and receives a relatively large pressing force. The elastic modulus of each elastic member 31, 32 is such that the thickness of the compressed first elastic member 31 and the thickness of the second elastic member 32 compressed by receiving a relatively small pressing force are approximately the same. Adjust. Thereby, even when there is a difference in the magnitude of the pressing force received depending on the position of the protrusion 22, it is possible to prevent the depth at which each protrusion 22 pierces the skin from varying.

  Further, for example, in the administration site of the drug facing the support surface 21S, the skin is more easily stretched at the outer peripheral portion than at the central portion, and the skin is stretched more at the outer peripheral portion than at the central portion due to the pressing force. When the protruding portion 22 is pierced, there is a case where the protruding portion 22 pierces the skin deeper in the outer peripheral portion than in the central portion when the pressing force is weakened. Therefore, in a state where the protrusion 22 is deeply stabbed into the skin due to the pressing force, the protrusion 22 located on the outer periphery of the support surface 21S is shallower than the protrusion 22 located at the center of the support surface 21S. Try to sting. That is, the first elastic member 31 is an elastic body having a larger elastic modulus than that of the second elastic member 32, or the first elastic member 31 is an elastic body having a maximum length T larger than that of the second elastic member 32. The thickness of the first elastic member 31 is set to be greater than the thickness of the second elastic member 32 in a state where the protrusion 22 is deeply stabbed into the skin under pressure. Thereby, in a state where the pressing force is weakened and the skin stretches back, it is possible to prevent the depth at which each protrusion 22 pierces the skin from varying.

  In addition, as a structure for suppressing the dispersion | variation in the depth stuck in the skin of the projection part 22 by the difference in the arrangement position of the projection part 22 in the center part of this support surface 21S and an outer peripheral part, a characteristic differs as mentioned above. In addition to the configuration in which the two types of elastic members 30 are disposed, a configuration in which the protrusions 22 are disposed only on the outer peripheral portion of the support surface 21S can be suitably used as shown in FIGS.

  Further, by making the first elastic member 31 and the second elastic member 32 different in adhesiveness, the strength with which the transdermal administration device 10 sticks to the skin is adjusted according to the position in the support surface 21S. Also good. For example, the elastic member tends to be peeled off as the portion located on the outer side in the administration site is increased. On the other hand, if the adhesiveness of the first elastic member 31 is greater than the adhesiveness of the second elastic member 32, the outer peripheral portion of the support surface 21S and the portion facing the central portion of the support surface 21S Since the transdermal administration device 10 sticks strongly to the skin at the facing portion, the transdermal administration device 10 can be prevented from peeling off from the skin before and during the administration of the drug.

  The shape and number of each of the first elastic member 31 and the second elastic member 32 may be set according to the characteristics that are different between the first elastic member 31 and the second elastic member 32 and the purpose thereof. In addition to the above example, for example, when it is desired to change the depth of the protrusion 22 in the skin depending on the position within the support surface 21S, or when the maximum length H of the protrusion 22 varies depending on the position within the support surface 21S, etc. In addition, two types of elastic members 30 having different characteristics may be used depending on the purpose. Further, three or more types of elastic members 30 having different characteristics may be disposed on the support surface 21S. The plurality of elastic members 30 arranged on the support surface 21S are elastic members 30 in which two or more of the magnitude of the elastic modulus, the adhesive strength, and the maximum length T of the elastic member 30 are different. May be.

  Further, as long as the elastic member 30 is positioned on the support surface 21S, the elastic member 30 may not surround the protrusion 22 alone, and may not be disposed along the outer edge of the support surface 21S.

  For example, as shown in FIG. 25 and FIG. 26, a plurality of elastic members 30 may be arranged on the support surface 21 </ b> S, and the elastic members 30 may be located in a region between the plurality of protrusions 22. When the plurality of protrusions 22 are evenly arranged around the center of the support surface 21S on the support surface 21S, the plurality of elastic members 30 are also equally arranged around the center of the support surface 21S. It is preferable. The shape and number of the elastic members 30 may be set as appropriate according to the arrangement of the plurality of protrusions 22.

  Even when the elastic member 30 does not surround the protrusion 22 alone, two or more types of elastic members 30 having different characteristics may be arranged on the support surface 21S.

  For example, as shown in FIG. 27 and FIG. 28, a plurality of first elastic members 31 are arranged on the outer peripheral portion of the support surface 21 </ b> S, and a plurality of regions are arranged in a region inside the region where the first elastic members 31 are arranged. The second elastic member 32 is disposed.

  In each of the above embodiments, the configuration in which the shape of the support surface 21S is circular has been illustrated, but the support surface 21S may be rectangular or elliptical depending on the shape of the base portion 21. Good. Regardless of the shape of the support surface 21S, the elastic member 30 may be arranged in the same manner as in the above embodiment.

  For example, FIGS. 29 to 36 show examples in which the support surface 21S has an elliptical shape. As shown in FIGS. 29 and 30, the elastic member 30 may surround a set of a plurality of protrusions 22, and as shown in FIGS. 31 and 32, the elastic member 30 includes a plurality of protrusions. 22 may be surrounded one by one. For example, as FIG. 33-36 shows, the elastic member 30 does not surround the projection part 22 independently, and the some elastic member 30 may be arrange | positioned at the support surface 21S. As shown in FIGS. 33 and 34, the elastic member 30 may be disposed between the plurality of protrusions 22, and as shown in FIGS. 35 and 36, the elastic member 30 includes a plurality of protrusions. It may be arranged around 22. For example, two types of elastic members 30 having different characteristics may be arranged on the support surface 21S.

  29 to 36 exemplify a configuration in which the shape of the protruding portion 22 is a substantially quadrangular pyramid shape, but the shape of the protruding portion 22 is not limited to the shape of the supporting surface 21S, as described above. Any shape that can be stabbed is acceptable.

  In the embodiment described with reference to FIGS. 1 to 3, the length of the elastic member 30 in the direction in which the protrusion 22 extends is constant in the elastic member 30. May change in the elastic member 30. That is, the elastic member 30 may have a plurality of portions in which the length of the elastic member 30 is different from each other.

  For example, as shown in FIGS. 37 and 38, the elastic member 30 has an annular shape surrounding a set of the plurality of protrusions 22, and is an elastic member in a direction in which the protrusions 22 extend from the outside in the radial direction to the inside. You may have the part which length of 30 becomes small gradually. In other words, when viewed from the direction facing the support surface 21S, the elastic member 30 may have an inclined surface that approaches the support surface 21S toward the inner peripheral edge of the elastic member 30.

  According to such a configuration, for example, the following effects can be obtained. In other words, after the transdermal administration device 10 is pressed against the skin, when the pressing force is weakened, the skin surface sticks to the inclined surface of the elastic member 30, so that the gap between the inclined surface and the protrusion 22 is reduced. The skin is lifted so that the skin enters the space. Therefore, since the skin is lifted around the protrusion 22, it is possible to suppress leakage of the drug and peeling of the transdermal administration device 10 from the skin.

  The inclination angle of the inclined surface with respect to the extending direction of the protrusion 22 may be set as appropriate according to the ease of extension of the skin at the administration site. Further, the inclined surface may be a flat surface as in the example shown in FIG. 37, or may be a curved surface as in the example shown in FIG. In FIGS. 37 and 38, the length of the elastic member 30 in the extending direction of the protruding portion 22 becomes constant from the radially outer side to the inner side of the elastic member 30 and then gradually decreases. That is, the elastic member 30 seen from the direction facing the support surface 21S is composed of a plane parallel to the support surface 21S and the inclined surface, but the elastic member 30 does not have to have such a plane. The length of 30 may always gradually decrease from the outside in the radial direction toward the inside.

  A plurality of elastic members 30 may be stacked in the direction in which the protrusion 22 extends. For example, in the example shown in FIG. 39, the first elastic member 33, the second elastic member 34, which are the elastic members 30 each of which is annular and surrounds the set of the plurality of protrusions 22, in order from the position close to the support surface 21S. The third elastic members 35 are arranged. When viewed from the direction facing the support surface 21S, the outer peripheral edges of the elastic members 33, 34, and 35 match, and the inner peripheral edges of the elastic members 33, 34, and 35 are elastic members close to the support surface 21S. About 30 are located inside. That is, as viewed from the direction facing the support surface 21S, the inner peripheral edge of the third elastic member 35, the inner peripheral edge of the second elastic member 34, and the inner peripheral edge of the first elastic member 33 are located in order from the outside in the radial direction. Yes.

  Even with such a configuration, as shown in FIGS. 37 and 38, the elastic member 30 has a portion in which the length in the extending direction of the protrusion 22 gradually decreases from the outer side in the radial direction to the inner side. The same effect as the configuration can be obtained. The plurality of elastic members 30 may include elastic members 30 having different properties such as elastic modulus and adhesiveness. According to such a structure, the compression shape in the laminated body of the elastic member 30 when the transdermal administration device 10 is pressed against the skin and how to stick to the skin can be finely adjusted.

  As shown in FIG. 40, the elastic member 30 may have a portion in which the length of the elastic member 30 in the extending direction of the protrusion 22 gradually decreases from the inner side to the outer side in the radial direction. . In other words, the elastic member 30 may have an inclined surface that approaches the support surface 21S toward the outer peripheral edge of the elastic member 30 when viewed from the direction facing the support surface 21S.

  According to such a configuration, for example, the following effects can be obtained. That is, in the vicinity of the outer peripheral edge of the elastic member 30, the pressure of the skin by the elastic member 30 is weakened, so that it is possible to prevent the skin from extending excessively at the outer peripheral portion where the skin is easily stretched in the administration site. Variations in the degree of skin elongation can be suppressed.

  In addition, the inclination angle of the inclined surface with respect to the extending direction of the protrusion 22 may be appropriately set according to the ease of elongation of the skin at the administration site, and the inclined surface may be a flat surface or a curved surface. The elastic member 30 may or may not have a portion where the length of the elastic member 30 in the extending direction of the protrusion 22 is constant as in the example shown in FIG. . That is, the elastic member 30 seen from the direction facing the support surface 21S may be configured by a plane parallel to the support surface 21S and the inclined surface, or the elastic member 30 may not have such a plane. The length of the elastic member 30 may always gradually decrease from the inside in the radial direction toward the outside.

  As shown in FIG. 41, the elastic member 30 includes a portion where the length of the elastic member 30 in the extending direction of the protrusion 22 gradually decreases from the outer side in the radial direction and the inner side in the radial direction. You may have the part which becomes small gradually toward the outer side. In other words, when viewed from the direction facing the support surface 21 </ b> S, the elastic member 30 has an inclined surface that approaches the support surface 21 </ b> S toward the inner peripheral edge of the elastic member 30, and the support surface 21 </ b> S toward the outer peripheral edge of the elastic member 30. It may have an inclined surface approaching. In the example shown in FIG. 41, the length of the elastic member 30 in the extending direction of the protrusion 22 gradually increases from the radial direction outer side to the inner side of the elastic member 30 and then remains constant. It is getting smaller gradually. The elastic member 30 may not have a portion where the length of the elastic member 30 is constant, that is, the elastic member 30 is parallel to the support surface 21S when viewed from the direction facing the support surface 21S. It is not necessary to have a flat surface.

  42 and 43, the elastic member 30 has an inclined surface at a position facing the support surface 21S, so that the length of the elastic member 30 in the extending direction of the protrusion 22 is the radial direction. A portion that gradually decreases from the outside to the inside or a portion that gradually decreases from the inside in the radial direction to the outside may be formed. 42 and 43, the elastic member 30 includes an inclined surface that approaches the support surface 21S toward the inner periphery of the elastic member 30 and an outer periphery of the elastic member 30 when viewed from the direction facing the support surface 21S. Toward the support surface 21S, toward the inner peripheral edge of the elastic member 30, toward the inner peripheral edge of the elastic member 30, and toward the outer peripheral edge of the elastic member 30. And an inclined surface separated from the support surface 21S.

As shown in FIG. 42, these inclined surfaces in the cross section along the extending direction of the protruding portion 22, with respect to each of the straight line along the extending direction of the protruding portion 22 and the straight line along the direction orthogonal to this direction. As shown in FIG. 43, they may be arranged asymmetrically with respect to each of these straight lines.
42 and 43, the elastic member 30 may protrude from the outer edge of the support surface 21S when viewed from the direction facing the support surface 21S.

[Configuration of drug administration device]
The configuration of the drug administration device will be described with reference to FIGS. The drug administration device includes the above-described transdermal administration device 10 and an administration aid wrapped around a drug administration target.
The configuration of the administration aid will be described with reference to FIGS.

  As shown in FIG. 44, the administration aid 50 defines a band part 51 extending in a band shape, a fixing part 52 configured to fix both end parts in the extending direction of the band part 51 to each other, and a drug administration position. And an administration position defining portion 53.

  The band part 51 has the flexibility which can be wound around the limb of the medicine administration target. The material which comprises the band part 51 will not be specifically limited if it is a material which can implement | achieve such flexibility, As a material, for example, polyvinyl chloride, polyethylene, a polypropylene, polybutadiene, an ethylene-vinyl acetate copolymer ( Examples thereof include polyolefins such as EVA), polyesters such as polyethylene terephthalate (PET) and polybutylene terephthalate (PBT), various thermoplastic elastomers such as polyvinylidene chloride, silicon, polyurethane, polyamide elastomer, polyurethane elastomer, and polyester elastomer. In addition, it is preferable that the band part 51 has the transparency which can visually recognize the skin of the part around which the band part 51 is wound. Thereby, since each site | part of skin can be visually recognized from the outer side of the administration assistance tool 50, confirmation of the administration position of a chemical | medical agent at the time of fixing the administration assistance tool 50 to a limb, and confirmation of the position where the chemical | medical agent was administered Etc. are easy. The length of the band part 51 should just be the length according to the part of the limb where the administration site | part of a chemical | medical agent is located.

  The fixing portion 52 has a structure for fixing two end portions in the extending direction of the band portion 51 to each other. For example, the fixing portion 52 is a hook-and-loop fastener composed of two fixing portions 52 a and 52 b, and the fixing portion 52 a on the male side of the hook-and-loop fastener is attached to one of the two end portions on the surface of the band portion 51. The fixing portion 52 b that is located and is the female side of the hook-and-loop fastener is located on the other of the two end portions on the back surface of the band portion 51. Note that the fixing portion 52 is not limited to a hook-and-loop fastener, and may be a frame-like member that is fastened through two end portions of a snap button, a button and a button hole, a clip, and a band portion 51, for example.

  The administration position defining portion 53 includes an opening 54 provided at the center in the extending direction of the band portion 51 and a lid 55 provided so as to be able to be opened and closed so as to close the opening 54. The opening 54 has such a size that the support surface 21S of the transdermal administration device 10 can be inserted. For example, the opening 54 has a size substantially equal to the support surface 21S.

  Around the opening 54, a structure for fixing the band portion 51 in a state where the lid portion 55 is closed is provided. The lid 55 protects the administration site of the drug at a position facing the skin within the opening 54 when the lid 55 is closed, and suppresses the administered drug from leaking to the surface of the skin. A protection unit 56 is provided.

  The protection part 56 is comprised from the plate-shaped auxiliary member for pressing the pad member which has air permeability and moisture absorption like gauze and sponge, and a pad member to skin, for example. When a sponge is used as the pad member, the water absorption swelling rate of the sponge is preferably 100% or more, and more preferably 300% or more. Further, the thickness of the sponge at the time of drying is preferably 0.5 mm or more, and more preferably 0.8 mm or more. The sponge preferably has a biocompatible material, and such a sponge is preferable because a cellulose sponge is easily available. It should be noted that a sheet having water repellency or the like may be included in the protection unit 56 in order to prevent excessive absorption of the medicine to which the pad member has been administered.

As shown in FIG. 45 and FIG. 46, the band portion 51 is wound around the limb Li so as to go around the wrist and arm that are the limb Li, and the fixing portion 52a is overlapped with the fixing portion 52b so that these By fixing the fixing portions 52a and 52b to each other, the administration aid 50 is fixed to the limb Li. At this time, the position of the band part 51 with respect to the limb Li is determined so that the opening 54 of the administration position defining part 53 is disposed at a position where the medicine is to be administered.
As shown in FIG. 47, the drug administration device 40 includes a transdermal administration device 10 and an administration aid 50.

  When the drug administration device 40 is used for drug administration, the distal end portion of the outer cylinder 61 of the syringe 60 is connected to the cylinder end of the base 21 of the transdermal administration device 10 opposite to the support surface 21S. It suffices if a structure for connecting the distal end portion of the outer cylinder 61 is provided at the cylinder end of the base portion 21.

  The transdermal administration device 10 is inserted into the opening 54 with the support surface 21S facing the opening 54, and the protrusion 22 is stabbed into the skin. When the piston 62 of the syringe 60 is pressed, the medicine accommodated in the outer cylinder 61 is supplied to the inside of the base portion 21, and further, the medicine passes through the through hole 23 and comes out from the tip of the projection portion 22. The outer cylinder 61 of the syringe 60 is transparent or translucent, and the outer cylinder 61 is provided with a scale indicating the filling amount of the medicine, so that the amount of medicine filled in the outer cylinder 61 is confirmed from the outside. It is easy to accurately administer the desired amount of drug.

  Note that the instrument for supplying the drug to the base portion 21 is not limited to the syringe 60, and a tool that allows the drug to flow through the inside of the base portion 21 and the through hole 23 by pressure and be released from the tip of the protrusion 22. If it is.

  As shown in FIG. 48, the transdermal administration device 10 before being used for drug administration, that is, before being inserted into the opening 54 of the administration aid 50 after being assembled into the syringe 60, is covered by the cover member 70. It is preferably protected. The cover member 70 has a shape that covers the surface of the elastic member 30 opposite to the surface in contact with the support surface 21S and the portion of the protrusion 22 that protrudes from the elastic member 30 and is elastic. Affixed to the member 30 so as to be peelable.

  For example, the cover member 70 has a recess surrounding the protruding portion 22 protruding from the elastic member 30 and a surface on the opposite side of the surface protruding from the end of the recess and contacting the support surface 21S of the elastic member 30. It consists of a part to be pasted. In addition, it is preferable that the cover member 70 has a portion that can be picked with a finger when the cover member 70 is peeled off from the elastic member 30 because the cover member 70 can be easily peeled off.

  Although the material which comprises the cover member 70 is not specifically limited, As a material, resin which can perform the shaping | molding by injection molding process or press work easily is preferable. Moreover, it is preferable that the cover member 70 is transparent or translucent because the inside of the cover member 70 can be visually recognized from the outside. Moreover, it is preferable that the cover member 70 has small permeability of air and water vapor and can stably protect the transdermal administration device 10 over a long period of time. Polyethylene terephthalate (PET), polypropylene (PP), and polyethylene (PE) are preferably used as a material that can realize such a cover member 70. In particular, PET is deteriorated or emitted by γ-ray or electron beam irradiation sterilization. Since there is little odor, it is preferable.

  By storing the transdermal administration device 10 in a state of being covered with the cover member 70, it is possible to suppress a decrease in the adhesiveness of the surface of the elastic member 30 to be affixed to the skin, and the protrusion 22 is an external article. It is possible to suppress deformation due to contact with the like.

[Drug administration using drug administration device]
With reference to FIG. 49 to FIG. 52, a procedure of drug administration using the drug administration device 40 will be described.
The user of the drug administration device 40 fixes the administration aid 50 to the limb of the administration target so that the opening 54 is disposed at a position where the drug is to be administered. At this time, as shown in FIG. 49, the lid 55 is opened, and the skin Sk is exposed in the opening 54. A syringe 60 filled with the medicine M is connected to the transdermal administration device 10, and the user opens the transdermal administration device 10 with the tip of the protrusion 22 facing the skin Sk exposed in the opening 54. Insert into part 54 and press against skin Sk.

  As shown in FIG. 50, the protruding portion 22, the elastic member 30, the supporting surface 21S, and the base portion 21 near the supporting surface 21S are inserted into the opening 54, and the protruding portion 22 penetrates the stratum corneum and the skin. Sting the Sk. At this time, the elastic member 30 contacts the surface of the skin Sk in a state where the elastic member 30 is compressed in the extending direction of the protruding portion 22 under a pressing force. The user presses the transdermal administration device 10 strongly against the skin Sk and then weakens the pressing force.

  As shown in FIG. 51, when the user weakens the pressing force applied to the transdermal administration device 10, the elastic member 30 is restored, and the base portion 21 and the protruding portion are increased as the thickness of the elastic member 30 increases. 22 moves away from the surface of the skin Sk. At this time, since the elastic member 30 is adhered to the surface of the skin Sk, the protrusion 22 is prevented from slipping out of the skin Sk or the protrusion 22 is tilted in the skin Sk.

  Thereby, the press with respect to skin Sk is weakened, and a user presses piston 62 of syringe 60 in this state. As a result, the medicine M supplied from the syringe 60 to the internal space of the base body portion 21 passes through the inside of the base body portion 21 and the through hole 23, exits from the tip of the protrusion 22, and is diffused into the skin. Since the pressure on the skin Sk is weakened, the drug can easily diffuse into the skin, so that the drug can be smoothly administered. In addition, since the administration assisting device 50 defines the scheduled administration position of the drug at the position of the opening 54, and the drug 22 can be determined by piercing the skin Sk according to the position of the opening 54, the drug administration position can be determined. It is easy to position the position to administer. Further, since the protrusion 22 and the support surface 21S are located in the opening 54 even during the administration of the drug, the stability of the position of the transdermal administration device 10 with respect to the skin Sk is improved.

  As shown in FIG. 52, when the administration of the medicine is completed, the user pulls up the transdermal administration device 10 from the opening 54 and closes the lid 55. Thereby, the protection part 56 contacts the administration site of the drug in the skin Sk, the administration site of the drug is protected, and the administered drug is prevented from leaking to the surface of the skin Sk. Therefore, penetration of the administered drug into the body is assisted.

  Note that the drug may be administered using the transdermal administration device 10 without using the administration aid 50. However, as described above, the administration of the drug can be easily performed by using the administration aid 50. It can be performed.

As described above, according to the transdermal administration device and drug administration device of the present embodiment, the following effects can be obtained.
(1) Since the elastic member 30 is disposed on the support surface 21S, when the transdermal administration device 10 is pressed against the skin to such an extent that the protrusion 22 is stuck in the skin to be administered, the support surface 21S and the surface of the skin The elastic member 30 sticks to the surface of the skin in a state where the elastic member 30 is compressed therebetween. When the pressing force applied to the transdermal administration device 10 is weakened, the base portion 21 and the protruding portion 22 move away from the skin surface as the shape of the elastic member 30 is restored. The pressure on the skin by the transdermal administration device 10 is weakened. At this time, since the elastic member 30 is adhered to the surface of the skin, it is possible to prevent the support surface 21S from being excessively separated from the surface of the skin and, in turn, the protruding portion 22 from slipping out of the skin. Therefore, while applying a force to penetrate the stratum corneum and piercing the protrusion 22 into the skin, the drug penetrates into the skin by reducing the pressure on the skin while suppressing the pierced protrusion 22 from coming out of the skin. In this state, by administering the drug through the through hole 23, the drug can be smoothly administered.

  (2) In the configuration in which the elastic member 30 surrounds the protrusion 22 when viewed from the direction facing the support surface 21S, the transdermal administration device 10 sticks to the skin at a position surrounding the protrusion 22. Therefore, the stability of the position of the protrusion 22 with respect to the skin is improved.

  (3) When viewed from the direction facing the support surface 21S, the structure in which the elastic member 30 surrounds the set of the plurality of protrusions 22 is compared to the structure in which the elastic member 30 surrounds the protrusions 22 one by one. Further, since the shape of the elastic member 30 is complicated and it is difficult to obtain the shape accuracy of the elastic member 30, it is easy to form the elastic member 30.

  (4) When viewed from the direction facing the support surface 21S, the configuration in which the elastic member 30 surrounds the protrusions 22 one by one is compared with the configuration in which one elastic member 30 surrounds a set of the plurality of protrusions 22. Thus, it is easy to secure a large area occupied by the elastic member 30 on the support surface 21S. Therefore, since it is easy to ensure a large area of the elastic member 30 attached to the surface of the skin, the stability of the position of the protrusion 22 with respect to the skin is enhanced.

  (5) In the configuration in which the transdermal administration device 10 includes a plurality of elastic members 30, the degree of freedom in adjustment of the arrangement of the elastic members 30 and the functions exhibited by the elastic members 30 is increased.

  (6) The plurality of elastic members 30 include elastic members having different elastic moduli, elastic properties of the elastic members 30, and different lengths of the elastic members 30 in the direction in which the protrusions 22 extend. According to such a configuration, the length of the protrusion 22 to be pierced by the skin is adjusted in accordance with variations in pressing force depending on the position in the support surface 21S, variations in the easiness of the skin in the drug administration site, and the like. In addition, the strength with which the transdermal administration device 10 sticks to the skin can be adjusted according to the position within the support surface 21S.

  (7) In the configuration in which the elastic member 30 has a plurality of portions in which the length of the elastic member 30 in the extending direction of the protrusion 22 is different, the protrusion 22 that pierces the skin according to the position in the support surface 21S. The length and the elongation of the skin can be adjusted, and how the transdermal administration device 10 is attached to the skin can be adjusted.

  (8) The transdermal administration device 10 is used together with the administration aid 50, and the administration aid 50 is wound around the administration target of the medicine, and then the transdermal administration device 10 is inserted into the opening 54 to insert the protrusion 22 into the opening 54. By piercing the inner skin and administering the drug, it is possible to easily position the transdermal administration device 10 with respect to the skin, that is, the position where the drug is administered. In addition, the stability of the position of the transdermal administration device 10 with respect to the skin during the administration of the drug is improved. Furthermore, by closing the opening 54 with the lid portion 55 after the administration of the drug, penetration of the administered drug into the body is assisted. Therefore, smooth drug administration using the transdermal administration device 10 can be facilitated.

  DESCRIPTION OF SYMBOLS 10 ... Transdermal administration device, 20 ... Microneedle, 21 ... Base | substrate part, 21S ... Support surface, 22 ... Protrusion part, 23 ... Through-hole, 30 ... Elastic member, 40 ... Drug administration instrument, 50 ... Administration aid, 51 ... Band part, 52 ... Fixing part, 53 ... Administration position defining part, 54 ... Opening part, 55 ... Lid part, 60 ... Syringe, 70 ... Cover member.

Claims (8)

A cylindrical base part for passing a medicine, the base part having a support surface at one of two cylindrical ends of the base part;
A protrusion protruding from the support surface, the protrusion being formed with a through-hole penetrating the protrusion in the extending direction of the protrusion and communicating with the internal space of the base body;
An elastic member which is an elastic body located on the support surface and having adhesiveness;
A transdermal administration device comprising: The transdermal administration device according to claim 1, wherein the elastic member surrounds the periphery of the protrusion when viewed from a direction facing the support surface. The transdermal administration device comprises a plurality of the protrusions,
The transdermal administration device according to claim 2, wherein the elastic member surrounds a set of the plurality of protrusions when viewed from a direction facing the support surface. The transdermal administration device comprises a plurality of the protrusions,
The transdermal administration device according to claim 2, wherein the elastic member surrounds the protrusions one by one when viewed from a direction facing the support surface. The transdermal administration device according to claim 1, wherein the transdermal administration device includes a plurality of the elastic members. The plurality of elastic members include a plurality of elastic members having different characteristics, and the characteristics include the elastic modulus of the elastic member, the adhesiveness of the elastic member, and the elasticity in the extending direction of the protrusion. The transdermal administration device according to claim 5, wherein the transdermal administration device is at least one of the maximum lengths of the members. The transdermal administration device according to claim 1, wherein the elastic member has a plurality of portions each having a different length of the elastic member in the extending direction of the protrusion. A transdermal administration device according to any one of claims 1 to 7,
A drug administration device comprising: an administration aid wrapped around a drug administration target,
The administration aid is
A band portion extending in a band shape;
An opening formed in the band, the opening having a size capable of inserting the support surface of the transdermal administration device, and a lid that can be opened and closed so as to close the opening An administration position defining part;
A drug administration device comprising: a fixing part configured to fix both end parts of the band part in a direction in which the band part extends.